文献速递帕金森病与运动障碍

换挡:DBS能否用于帕金森病多巴胺能脱敏?

Changing Gears - DBS For Dopaminergic Desensitization in Parkinson's Disease?
PubMed 文献 · Ann Neurol · 2021-07-20

综述提出帕金森病长期多巴胺能治疗导致多巴胺能敏化,引发运动与神经精神并发症。总结STN-DBS可减少术后药物用量,支持多巴胺能脱敏。建议在出现多巴胺能并发症首个临床征象后、不可逆社会心理后果前早期考虑STN-DBS,并将神经精神并发症作为新纳入标准待验证。

要点

  • 多巴胺能敏化是长期多巴胺能治疗的运动与神经精神并发症共同机制
  • STN-DBS通过术后减药支持多巴胺能脱敏而非神经保护
  • 建议出现多巴胺能并发症首个临床征象后尽早考虑STN-DBS

核心结论

  • STN-DBS可通过术后减少多巴胺能药物用量支持多巴胺能脱敏,从而可能减少纵向运动与神经精神症状表达,而非通过神经保护。

研究设计与样本

  • 综述总结帕金森病多巴胺能敏化的临床表现与STN-DBS现状,提出「换挡」观点。

主要发现

  • 多巴胺能敏化在运动域表现为剂末反跳和异动症,在神经精神域表现为神经精神波动、行为成瘾伴冲动控制障碍和多巴胺失调综合征。
  • STN-DBS允许多巴胺能药物逐渐减量,从而支持多巴胺能脱敏。

关键数值与推荐

  • 建议在患者出现多巴胺能并发症首个临床征象后、但尚未遭遇潜在不可逆社会心理后果前,足够早地考虑STN-DBS。
  • 提出在既有运动标准之外,将神经精神多巴胺能并发症作为新的纳入标准,但需未来临床试验验证。

临床怎么用

  • 对出现多巴胺能运动或神经精神并发症早期征象的帕金森病患者,可重新思考更早使用STN-DBS。
  • STN-DBS术后应配合多巴胺能药物减量以支持脱敏。

局限性

  • 「换挡」观点为整合性可争议观点,将神经精神并发症作为纳入标准需未来临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In Parkinson's disease, both motor and neuropsychiatric complications unfold as a consequence of both incremental striatal dopaminergic denervation and intensifying long-term dopaminergic treatment. Together, this leads to 'dopaminergic sensitization' steadily increasing motor and behavioral responses to dopaminergic medication that result in the detrimental sequalae of long-term dopaminergic treatment. We review the clinical presentations of 'dopaminergic sensitization', including rebound off and dyskinesia in the motor domain, and neuropsychiatric fluctuations and behavioral addictions with impulse control disorders and dopamine dysregulation syndrome in the neuropsychiatric domain. We summarize state-of-the-art deep brain stimulation, and show that STN-DBS allows dopaminergic medication to be tapered, thus supporting dopaminergic desensitization. In this framework, we develop our integrated debatable viewpoint of "changing gears", that is we suggest rethinking earlier use of subthalamic nucleus deep brain stimulation, when the first clinical signs of dopaminergic motor or neuropsychiatric complications emerge over the steadily progressive disease course. In this sense, subthalamic deep brain stimulation may help reduce longitudinal motor and neuropsychiatric symptom expression - importantly, not by neuroprotection but by supporting dopaminergic desensitization through postoperative medication reduction. Therefore, we suggest considering STN-DBS early enough before patients encounter potentially irreversible psychosocial consequences of dopaminergic complications, but importantly not before a patient shows first clinical signs of dopaminergic complications. We propose to consider neuropsychiatric dopaminergic complications as a new inclusion criterion in addition to established motor criteria, but this concept will require validation in future clinical trials. ANN NEUROL 2021;90:699-710.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Weiss D, Volkmann J, Fasano A, et al. Changing Gears - DBS For Dopaminergic Desensitization in Parkinson's Disease? Ann Neurol. 2021. PMID: 34235776. doi:10.1002/ana.26164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。